<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01643772</url>
  </required_header>
  <id_info>
    <org_study_id>OXYC09-CN-102</org_study_id>
    <nct_id>NCT01643772</nct_id>
  </id_info>
  <brief_title>OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) Study</brief_title>
  <official_title>OxyNorm® Capsules (Immediate-Release) PK Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma (China) Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma (China) Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single Dose PK Study of OxyNorm® immediate-release capsules 5, 10, and 20mg, and a
      multiple-dose PK Study of OxyNorm® immediate-release capsules 10mg in Chinese patients with
      pain.It will be a single center, open label, randomized, oral administration study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single dose: The subjects will be randomized to receive a single dose of OxyNorm®
      immediate-release capsules 5, 10, and 20mg.

      Multiple dose: The subjects will take 3 days OxyNorm® capsule 10mg, once every 6 hours, 10mg
      per dose. In the morning of the 4th day, the subjects will take single dose of OxyNorm®
      capsule 10mg. On the 5th day, all the subjects complete the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose.</time_frame>
    <description>To investigate the pharmacokinetic profile, dose-proportionality, and evaluate drug accumulation of Oxycodone Hydrochloride after single dose of OxyNorm® capsules.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC) of time frame for multi-dose: Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day.</measure>
    <time_frame>5 days</time_frame>
    <description>To investigate the pharmacokinetic profile, dose-proportionality, and evaluate drug accumulation of Oxycodone Hydrochloride after multiple dose of OxyNorm® capsules.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>OxyNorm® Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OxyNorm® Capsules (Oxycodone Hydrochloride)</intervention_name>
    <description>The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.</description>
    <arm_group_label>OxyNorm® Capsules</arm_group_label>
    <other_name>No other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pain, Multiple dose group should enroll the Patients with cancer pain;

          -  Patients aged &gt;≥30 to ≤ 60 years;

          -  Body weight ≥ 45kg, and BMI range ≥19, &lt;24;

          -  Karnofsky score ≥ 70;

          -  The results of liver function and kidney tests must meet the following criteria:
             ALT、AST is within the upper limit of normal value ranges by a factor 2, and TB、BUN、Cr
             is within the upper limit of normal value ranges by a factor 1.25;

          -  The electrocardiogram examination results are normal;

          -  Patients must have given a written informed consent prior to this trial, and have the
             capability to complete every required test.

        Exclusion Criteria:

          -  Have hypersensitivity history to any opioids;

          -  Have known hypersensitivity to any of compositions of the study drugs;

          -  Patients who are likely to have paralytic ileus or acute abdomen or to perform an
             operation on abdominal region；

          -  Patients with respiratory depression, cor pulmonale, or chronic bronchial asthma;

          -  Patients who are unable to stop taking monoamine oxidase inhibitor during this trial
             period or time lapses less than 2 weeks since drug withdrawal;

          -  Patients with hypercarbia;

          -  Patients with biliary tract diseases, pancreatitis, prostatic hypertrophy, or
             corticoadrenal insufficiency;

          -  Patients with alcoholism or drug abuse history;

          -  Positive anti-HIV or syphilis antibody test result;

          -  Patients who are pregnant, or lactating;

          -  Urine screening before study is positive for opioids, barbiturates, amphetamines,
             cocaine metabolites, methadone, diazepam and cannabinoids;

          -  Donated 400 mL or more of blood or blood products within 3 months prior to the start
             of the study, or donated 200 mL or more of blood or blood products within one month
             prior to the start of the study;

          -  Subjects who participated in a clinical research study within one month of study
             entry;

          -  Patients who are currently taking opioids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mundipharma China Ltd.</last_name>
    <role>Study Chair</role>
    <affiliation>Mundipharma China Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Affiliated Hospital to Academy of Military Medical Science of China People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>July 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2012</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 5, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

